Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (cyclophosphamide, oncovin, methotrexate, leucovorin, cytosine arabinoside): a 10-year experience in a single institution.
Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (cyclophosphamide, oncovin, methotrexate, leucovorin, cytosine arabinoside): a 10-year experience in a single institution.
复制标题
使用 COMLA（环磷酰胺、癌蛋白、甲氨蝶呤、甲酰四氢叶酸、阿拉伯胞嘧啶）治疗弥漫性组织细胞淋巴瘤 (DHL)：单一机构 10 年经验。
DOI：
--
复制
发表时间：
1985
影响因子：
45.3
通讯作者：
D. Sweet
中科院分区：
文献类型：
--
作者：
E. Gaynor;J. Ultmann;H. Golomb;D. Sweet
从1974年3月至1983年12月，83例弥漫性组织细胞淋巴瘤（DHL）患者接受COMLA治疗（环磷酰胺1.5g/m2，第1天; Oncovin（Lilly，Indianapolis）1.4mg/m2，第1、8和15天;阿糖胞苷300 mg/m2和甲氨蝶呤120 mg/m2，第22、29、36、43、50、57、64和71天;甲酰四氢叶酸25 mg/m2，每6小时× 4，从甲氨蝶呤后24小时开始）。为了进行分析，将患者分为两组。第1组（n = 54）包括65岁或以下的患者，既往未接受过根治性放疗或化疗。第2组（n = 29）包括所有年龄超过65岁的患者和既往接受过根治性放疗或既往接受过最低限度化疗的患者。所有患者的中位随访时间为28个月。第1组包括11例II期、10例III期和33例IV期患者。在该组的48例可评价患者中，21例（44%）达到完全缓解（CR），8例（17%）达到部分缓解（PR），19例（40%）无反应（NR）。CR患者的中位生存期为114+个月，PR患者为42个月，NR患者为13个月。6例CR患者复发。CR患者的中位无病生存期为108+个月。第2组包括9例II期、7例III期和13例IV期患者。在24例可评价缓解的患者中，8例（33%）达到CR，6例（25%）达到PR，10例（42%）无缓解。CR患者的中位生存期为114+个月，PR患者为17个月，NR患者为9个月。2例CR患者复发。CR患者的中位无病生存期尚未达到102个月。该方案在大多数患者中耐受性良好，毒性可接受。我们得出结论，COMLA是一种耐受性良好的门诊化疗方案，能够诱导持久的CR在一些患者的DHL。然而，COMLA取得的结果不如更积极的治疗方案;因此，COMLA作为DHL一线治疗的使用应仅限于无法耐受更积极治疗方案的患者。
Between March 1974 and December 1983, 83 patients with diffuse histiocytic lymphoma (DHL) were treated with COMLA (cyclophosphamide 1.5 g/m2 day 1; Oncovin (Lilly, Indianapolis) 1.4 mg/m2 days 1, 8, and 15; and cytosine arabinoside 300 mg/m2 and methotrexate 120 mg/m2 days 22, 29, 36, 43, 50, 57, 64, and 71; and leucovorin 25 mg/m2 every six hours X 4, beginning 24 hours after methotrexate). For the purpose of analysis, patients were divided into two groups. Group 1 (n = 54) included patients age 65 or under who had received no prior curative radiotherapy or chemotherapy. Group 2 (n = 29) included all patients over age 65 and patients who had received prior curative radiation therapy or prior minimal chemotherapy. The median time of follow-up for all patients was 28 months. Group 1 included 11 stage II, ten stage III, and 33 stage IV patients. Of 48 evaluable patients in this group, 21 (44%) achieved a complete remission (CR), eight (17%) achieved a partial remission (PR), and 19 (40%) showed no response (NR). Median survival of CR patients was 114+ months, PR patients, 42 months, and NR patients, 13 months. Six CR patients relapsed. The median disease-free survival of CR patients was 108+ months. Group 2 included nine stage II, seven stage III, and 13 stage IV patients. Of 24 patients evaluable for response, eight (33%) achieved a CR, six (25%) achieved a PR, and ten (42%) showed no response. The median survival of CR patients was 114+ months, that of PR patients was 17 months, and that of NR patients, 9 months. Two CR patients relapsed. The median disease-free survival of CR patients had not been reached at 102 months. The regimen was well tolerated in most patients and toxicity was acceptable. We conclude that COMLA is a well tolerated outpatient chemotherapy regimen capable of inducing durable CRs in some patients with DHL. Results achieved with COMLA, however, are inferior to those of more aggressive treatment programs; thus, the use of COMLA as first-line therapy in DHL should be limited to those patients unable to tolerate a more aggressive treatment program.
登录
查看更多内容
一项随机研究的后续行动，比较了晚期弥漫性组织细胞淋巴瘤的两种化疗方法。
DOI：
10.1200/jco.1984.2.9.986
发表时间：
1984
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Todd,M;Cadman,E;Spiro,P;Bertino,J;Farber,L;Waldron,J;Fischer,D
通讯作者：
Fischer,D
影响因子：
11.2
作者：
P. Carbone;H. Kaplan;K. Musshoff;D. Smithers;M. Tubiana
通讯作者：
P. Carbone;H. Kaplan;K. Musshoff;D. Smithers;M. Tubiana
局限性弥漫性组织细胞淋巴瘤患者的存活率。
影响因子：
20.3
作者：
Sweet,DL;Kinzie,J;Gaeke,ME;Golomb,HM;Ferguson,DL;Ultmann,JE
通讯作者：
Ultmann,JE
晚期弥漫性组织细胞淋巴瘤与六药 COP-BLAM 方案的联合化疗。
影响因子：
39.2
作者：
Laurence,J;Coleman,M;Allen,SL;Silver,RT;Pasmantier,M
通讯作者：
Pasmantier,M
影响因子：
45.3
作者：
ANDERSON, JR;CAIN, KC;GELBER, RD
通讯作者：
GELBER, RD